PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia

Weiping Qin, MD, PhD; Vahram Haroutunian, PhD; Pavel Katsel, PhD; Christopher P. Cardozo, MD; Lap Ho, PhD; Joseph D. Buxbaum, PhD; Giulio M. Pasinetti, MD, PhD

Objectives: To explore mechanisms through which altered peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α) expression may influence Alzheimer disease (AD) amyloid neuropathology and to test the hypothesis that promotion of PGC-1α expression in neurons might be developed as a novel therapeutic strategy in AD.

Design: Case-control.

Patients: Human postmortem brain (hippocampal formation) samples from AD cases and age-matched non-AD cases.

Results: Using genome-wide complementary DNA microarray analysis, we found that PGC-1α messenger RNA expression was significantly decreased as a function of progression of clinical dementia in the AD brain. Following confirmatory real-time polymerase chain reaction assay, we continued to explore the role of PGC-1α in clinical dementia and found that PGC-1α protein content was negatively associated with both AD-type neuritic plaque pathology and β-amyloid (Aβ)1-42 contents. Moreover, we found that the predicted elevation of amyloidogenic Aβ1-42 and Aβ1-40 peptide accumulation in embryonic cortico-hippocampal neurons derived from Tg2576 AD mice under hyperglycemic conditions (glucose level, 182-273 mg/dL) coincided with a dose-dependent attenuation in PGC-1α expression. Most importantly, we found that the reconstitution of exogenous PGC-1α expression in Tg2576 neurons attenuated the hyperglycemic-mediated β-amyloidogenesis through mechanisms involving the promotion of the “nonamyloidogenic” α-secretase processing of amyloid precursor protein through the attenuation of the forkheadlike transcription factor 1 (FoxO3a) expression.

Conclusion: Therapeutic preservation of neuronal PGC-1α expression promotes the nonamyloidogenic processing of amyloid precursor protein precluding the generation of amyloidogenic Aβ peptides.

Arch Neurol. 2009;66(3):352-361

Author Affiliations: Departments of Psychiatry (Drs Qin, Haroutunian, Katsel, Ho, Buxbaum, and Pasinetti), Medicine (Dr Cardozo), and Neuroscience (Drs Ho, Buxbaum, and Pasinetti), Mount Sinai School of Medicine, New York, and Geriatric Research Education and Clinical Center (Drs Ho and Pasinetti), James J. Peters VA Medical Center (Drs Ho and Pasinetti), Bronx, New York.

Alzheimer disease (AD) is a neurodegenerative disorder of the central nervous system. The neuropathological hallmarks of AD include extracellular amyloid-containing plaques and intracellular neurofibrillary tangles. The molecular events leading to the development of sporadic late-onset AD have not been defined. Advanced age is the largest AD risk factor and glucose/energy metabolism is decreased during aging. Recent evidence strongly supports the hypothesis that type 2 diabetes mellitus (T2D) is also a risk factor for AD. Moreover, recent evidence suggests that worsening in cerebral glucose metabolism is associated with progression of AD clinical dementia. Positron emission tomography studies demonstrated that glucose use is reduced markedly in the brain of mild cognitive impairment and early-stage AD. In contrast to controls, glucose ingestion significantly elevated hippocampal glucose concentrations in persons with AD, suggesting that cerebral glucose hypometabolism in AD results in increased steady-state concentrations of cerebral glucose. This evidence strongly associates brain glucose hypometabolic conditions and possibly T2D with the onset and progression of AD.

The present study was designed to explore mechanisms through which altered expression of peroxisome proliferator–activated receptor γ (PPAR-γ) coactivator 1α (PGC-1α), a key regulator of glu-
cose homeostasis in the liver and muscle during fasting or in conditions of insulin resistance in T2D through the activation of gluconeogenic metabolic pathways,73-83 may influence AD amyloid neuropathology and to test the hypothesis that promotion of PGC-1α expression in neurons might be developed as a novel therapeutic strategy in AD.

**METHODS**

**POSTMORTEM AD BRAIN FOR THE CHARACTERIZATION OF PGC-1α EXPRESSION IN THE AD BRAIN**

Human postmortem brain (hippocampal formation) samples from AD cases and age-matched non-AD cases were obtained from the Alzheimer’s Disease Brain Bank of the Mount Sinai School of Medicine. The precise tissue handling procedures have been described in detail previously (eTable 1, http://archneurol.com).34-36

**MICROARRAY PROCEDURE**

The procedures used for microarray analysis of gene expression in human hippocampal formation have been published previously (eTable 1).39-44

**CONFIRMATORY REAL-TIME POLYMERASE CHAIN REACTION STUDIES**

RNA was quantified by absorbance at 260/280 nm. One microgram of total RNA was used to prepare complementary DNA (cDNA) libraries using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, California) in a total volume of 20 µL. Data were normalized relative to those for neuron-specific enolase RNA (or glyceraldehyde-3-phosphate dehydrogenase [GAPDH] RNA) (eFigure). Levels of PGC-1α or forkheadlike transcription factor (FoxO) 3a messenger RNA (mRNA) were expressed relative to those in control groups using the 2−ΔΔCt method.45

**CONFIRMATORY WESTERN BLOT ANALYSIS**

Aliquots of crushed, never-thawed hippocampal formation tissue were extracted in phosphate-buffered saline containing final concentrations of 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 0.1mM edetic acid plus protease inhibitors. Antibodies used include PGC-1α (H-300, 1:500 dilution; Santa Cruz Biotechnology, Inc, Santa Cruz, California); anti-FKHL1 (FoxO3a) (1:1000 dilution; Upstate Biotechnology, Inc, Lake Placid, New York); polyclonal anti–amyloid precursor protein (APP) C terminal (751-770) antibody (anti-O443, 1:5000 dilution; Calbiochem, San Diego, California); monoclonal 6E10 antibody (H-300, 1:1000 dilution; Senetek, St Louis, Missouri); and monoclonal 22C11 antibody (1:1000 dilution; Senetek). In this study, β-actin immunoreactivity (1:1000 dilution; Sigma, St Louis) controlled for selectivity of changes. NIH/3T3+platelet-derived growth factor cell lysate (Santa Cruz Biotechnology) and DU145 nuclear extract (Santa Cruz Biotechnology) were used to assess specificity of detection in FoxO3a and PGC-1α immunoreactivity, respectively.

**QUANTIFICATION OF β-AMYLOIDx42 PEPTIDE CONTENT IN THE HUMAN BRAIN**

For the β-amyloid (Aβ) peptide assay, hippocampal formation frozen brain tissue samples were first pulverized in dry ice and cortical Aβx42 was extracted and quantified as previously described.46

**TISSUE CELL CULTURES**

Embryonic (E14) cortico-hippocampal primary neuronal cultures derived from Tg2576 transgenic mice (Tg2576 neurons) were prepared as previously described.47 To study the effect of glucose on amyloidogenesis, culture medium was replaced with Dulbecco modified Eagle medium in the presence of the desired concentration of glucose (91 mg/dL for normoglycemia condition and 182-273 mg/dL for hyperglycemia condition [to convert to millimoles per liter, multiply by 0.055]). For adenoviral infection studies, Tg2576 neuronal (5-day-old) (182-273 mg/dL) (hours after plating) cultures were infected with PGC-1α,48 constitutively active (CA) FoxO3a,49 or green fluorescent protein (GFP) control adenoviruses at doses defined as multiplicities of infection (MOI).

**CONFIRMATORY WESTERN BLOT ANALYSIS**

The quantitative assessment of Aβ peptides in primary cortico-hippocampal neuron cultures derived from embryonic Tg2576 mice was performed by enzyme-linked immunosorbent assays as previously described.50-52

**FLUORIMETRIC ASSESSMENT OF APP SECRETASE ACTIVITIES**

α-, β-, and γ-Secretase activities were assessed using commercially available kits (R&D Systems, Minneapolis, Minnesota) as previously described.51-54

**STATISTICAL ANALYSIS**

Analysis of variance (ANOVA) was used to evaluate differences in mean values among 3 or more groups, and the Dunnett t test was used to test the significance of differences between group pairs. One-tailed or 2-tailed tests were used as indicated. Correlation analysis between 2 variables was done using the Pearson parametric method followed by 2-way analysis of P value.

**RESULTS**

**IDENTIFICATION OF GENE PRODUCTS INVOLVED IN METABOLIC FUNCTIONS WHOSE EXPRESSION IS CHANGED AS A FUNCTION OF PROGRESSION OF CLINICAL AD DEMENTIA**

To clarify the molecular mechanisms involved in onset and progression of AD dementia, we used DNA microarray assays to identify candidate genes, the expression of which is altered in the AD brain at different stages of clinical dementia and neuropathology relative to controls without dementia. Among others, we report that we found a strong association between the altered expres-
sion of a series of gene products involved in glucose metabolism as well as in mitochondrial oxidative phosphorylation in the hippocampal formation of the AD brain. eTable 2 shows the alteration in gene expression involved in glucose metabolism and oxidative phosphorylation we found across all of the analyzed regions as a function of Clinical Dementia Rating (CDR). We report the association between the decreased expression of PGC-1α/H9251 in the AD brain as a function of progression of clinical dementia and AD neuropathology.

CONFIRMATORY EVIDENCE THAT HIPPOCAMPAL PGC-1α EXPRESSION IS DECREASED AS A FUNCTION OF AD CLINICAL DEMENTIA

The decreased expression in PGC-1α mRNA and eventually in PGC-1α protein content in the hippocampal for-

Figure 1. Hippocampal peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α) expression in the Alzheimer disease (AD) brain decreases as a function of AD dementia and AD β-amyloid (Aβ) neuropathology. A, PGC-1α messenger RNA (mRNA) content in the hippocampal formation (quantified by real-time reverse transcriptase–polymerase chain reaction and normalized by neuron-specific enolase [NSE]) as a function of Clinical Dementia Rating (CDR) representing cognitive normalcy (CDR=0), questionable dementia (CDR=0.5), mild dementia (CDR=2), and severe dementia (CDR=5). B, Western blot confirmation of decreased PGC-1α protein content in the hippocampal formation of AD cases. In A and B, data represent mean (SEM) and are shown as a percentage relative to the CDR=0 group. *P<.05, †P<.003, and ‡P<.01 vs control group by t-test. C and D, PGC-1α mRNA expression as a function of Aβ neuritic plaque neuropathology in accord with the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 4-point scale (n=4, 4, 3, and 3 for CERAD scores of 0, 1, 3, and 5, respectively) for AD (C) or content of Aβ42 (n=12) (D). Straight line represents best linear regression fit.

vere dementia (CDR=5) (P<.05 and P<.003, respectively) (Figure 1A and B and eTable 1). No detectable change in PGC-1α attenuation was found in cases at high risk to develop AD (mild cognitive impairment) (CDR=0.5) (Figure 1A and B).

DECREASED EXPRESSION OF HIPPOCAMPAL PGC-1α PROTEIN CONTENT CORRELATES WITH PROGRESSION OF AMYLOID NEUROPATHOLOGY IN AD

We found that the decreased PGC-1α protein content in the hippocampal formation of the cases examined correlated with the density of neuritic plaque (P<.05; r²=0.673; P<.001; n=14) (Figure 1C).

To further explore the functional relationship between the changes in hippocampal PGC-1α expression and amyloid neuropathology, we explored the relationship between PGC-1α protein content and Aβ peptide content in the brain of AD cases. We found that the hippocampal PGC-1α protein content inversely correlated with total Aβ₁₋₄₂ content in the EC-BM36/38 (Pearson correlation coefficient r²=−0.411; P=.02; n=12). This association tentatively suggests that a decrease in PGC-1α expression in the AD brain might be associated with conditions promoting AD Aβ amyloidogenesis.

HYPERGLYCEMIA-MEDIATED ATTENUATION OF PGC-1α EXPRESSION IN Tg2576 NEURONS COINCIDES WITH INCREASED Aβ PEPTIDE CONTENT IN THE CONDITIONED MEDIUM

We treated Tg2576 neurons with increasing glucose concentrations from 91 to 273 mg/dL in the culture-conditioned medium to match extracellular concentrations of glucose found in either normoglycemic (glucose concentration, 91 mg/dL) or hyperglycemic T2D conditions (glucose concentration, 182-273 mg/dL) in humans. We found that hyperglycemic conditions resulted in a significant decrease in PGC-1α protein content in the Tg2576 neurons in a dose-dependent manner (182 mg/dL, P<.05 and 273 mg/dL, P<.01), relative to control Tg2576 neurons cultured in normoglycemic conditions, 24 hours after treatment (Figure 2A).

The decreased PGC-1α protein content in Tg2576 neurons coincided with a significant dose-dependent elevation in endogenous Aβ₁₋₄₀ and Aβ₁₋₄₂ peptide contents in the Tg2576 neuron culture medium (182 mg/dL, P<.05 and 273 mg/dL, P<.01), relative to control Tg2576 neurons cultured in normoglycemic conditions, 24 hours after treatment (Figure 2B).

EXOGENOUS VIRAL EXPRESSION OF PGC-1α PREVENTS HYPERGLYCEMIA-MEDIATED POTENTIATION OF Aβ PEPTIDE ACCUMULATION IN THE CONDITIONED MEDIUM IN Tg2576 NEURONS

To further explore the role of PGC-1α in the promotion of Aβ peptide content in vitro, we tested the hypothesis that exogenous expression of PGC-1α in Tg2576 neurons might attenuate hyperglycemia-mediated accumulation of Aβ₁₋₄₀ and Aβ₁₋₄₂ content toward levels found in Tg2576 neurons cultured in control normoglycemic conditions.

We found that exogenous adenoviral expression (10 MOI) of PGC-1α resulted in approximately a 2- to 3-fold elevation in PGC-1α protein content in the Tg2576 neuron cultures, relative to control normoglycemic GFP adenoviral–expressing Tg2576 neurons (Figure 2C). Exogenous expression of PGC-1α significantly reduced the hyperglycemia-mediated attenuation of PGC-1α protein expression in Tg2576 neurons (Figure 2C), which coincided with a significant attenuation of Aβ₁₋₄₀ and Aβ₁₋₄₂ peptide content in the Tg2576 culture medium toward levels found in Tg2576 neurons cultured in control normoglycemic conditions, 24 hours after infection (Figure 2D). We also found that exogenous adenoviral expression of PGC-1α in Tg2576 neurons resulted in a moderate but significant decrease of Aβ₁₋₄₀ and Aβ₁₋₄₂ peptide content in the culture medium relative to control normoglycemic GFP adenoviral–expressing Tg2576 neurons (Figure 2D).

HYPERGLYCEMIC CULTURE CONDITIONS SELECTIVELY ATTENUATE α-SECRETASE ACTIVITY IN Tg2576 NEURONS

We found a selective attenuation of α- (P<.05), but not β- or γ-, secretase activity (Figure 3A) in GFP-expressing Tg2576 neurons cultured in hyperglycemic conditions for 24 hours, which coincided with a commensurate attenuation of 6E10 immunoreactive soluble APP-α (sAPPα) content in the culture-conditioned medium (P<.05), relative to Tg2576 neurons cultured in normoglycemic conditions (Figure 3A and B).

EXOGENOUS PGC-1α EXPRESSION PREVENTS HYPERGLYCEMIC-MEDIATED ATTENUATION OF NONAMYLOIDOGENIC α-SECRETASE PROCESSING OF APP IN Tg2576 NEURONS

Exogenous adenoviral PGC-1α expression in Tg2576 neurons cultured in normoglycemic conditions resulted in a selective elevation of α- (P<.05), but not β- or γ-, secretase activity (Figure 3A) coincidental with a significant increase in sAPPx content in the culture-conditioned medium (P<.005) relative to control GFP-expressing Tg2576 neurons cultured in normoglycemic conditions. Most importantly, we found that reconstitution of PGC-1α expression in Tg2576 neurons through exogenous adenoviral infection significantly prevented the hyperglycemic-mediated attenuation of α-secretase activity (Figure 3A) 24 hours after exogenous viral infection.

These changes occurred in the absence of detectable variations in the content of 22C11 immunoreactive (total) sAPP in the conditioned medium (Figure 3A) or in O-443 immunoreactive full-length APP in Tg2576 neurons (Figure 3C), excluding the possibility that exogenous adenoviral PGC-1α expression influenced total APP expression.

This evidence indicates that exogenous neuronal expression of PGC-1α might therapeutically reverse hyperglycemia-mediated attenuation of the nonamyloidogenic α-secretase processing of APP and diminish Aβ generation. The cerebral glucose hypometabolism reported in AD...
may result in increased steady-state levels of glucose in the brain\textsuperscript{20} that, through attenuation of PGC-1\textsubscript{α}/H9251 expression, might exacerbate AD A\textsubscript{β} amyloidogenesis.

Recent evidence supports the hypothesis that PGC-1\textsubscript{α} may influence muscle atrophy, in part through suppression of FoxO3a.\textsuperscript{55} Moreover, we recently found that exogenous expression of FoxO3a (10 MOI)\textsuperscript{48} in Tg2576 neurons may causally promote AD-type A\textsubscript{β} levels through mechanisms that attenuate nonamyloidogenic \textit{-}secretase processing of APP, suggesting an intrinsic association between FoxO3a activity and AD-type A\textsubscript{β} amyloidogenesis.\textsuperscript{56}

We found a significant elevation in FoxO3a protein content (\(P<.05\)) in GFP-expressing Tg2576 neurons cultured in hyperglycemic conditions relative to Tg2576 neurons cultured in normoglycemic conditions (Figure 4A) 24 hours after treatment. Most importantly, we found that exogenous adenoviral expression of PGC-1\textsubscript{α} significantly prevented the hyperglycemic-mediated potentiation of FoxO3a protein expression in Tg2576 neurons (Figure 4A) 24 hours after PGC-1\textsubscript{α} adenoviral infection.

We infected Tg2576 neurons with adenovirus-expressing CA FoxO3a or GFP control vector in combination with viral PGC-1\textsubscript{α} or control GFP infection in a culture-conditioned medium with 91 mg/dL of glucose. As expected, we found that Tg2576 neurons expressing exogenous viral PGC-1\textsubscript{α} resulted in a significant elevation of sAPP\textalpha{} content (\(P<.05\)) in the culture-conditioned me-
medium 24 hours after infection relative to control GFP-infected cells (P < .05) (Figure 4B).

Moreover, we found that exogenous CA FoxO3a (10 MOI) expression in Tg2576 neurons significantly prevented PGC-1α–mediated elevation of sAPPα (Figure 4B), relative to control GFP (and PGC-1α)-expressing Tg2576 neurons, in the absence of detectable changes in total sAPP in the conditioned medium (Figure 4B) or full-length cellular APP content (data not shown) 24 hours after infection.

Similarly, consistent with our previous findings,36 we found a significant diminution of sAPPα (P < .05) in the culture-conditioned medium of Tg2576 neurons virally expressing CA FoxO3a, but not PGC-1α, relative to control GFP-expressing Tg2576 neurons, further supporting the hypothesis of a direct inhibitory role of FoxO3a on the non-amyloidogenic α-secretase processing of APP (Figure 4B).

Collectively, this finding strongly supports the hypothesis that the transcription factor FoxO3a may be a downstream effector of PGC-1α and supports the hypothesis that decreased PGC-1α expression in the AD brain might result in increased FoxO3a expression in the brain eventually promoting AD Aβ amyloidogenesis.

PGC-1α EXPRESSION INVERSES CORRELATES WITH FoxO3a EXPRESSION IN THE AD BRAIN AS A FUNCTION OF PROGRESSION OF CLINICAL DEMENTIA

To further investigate the clinical relevance of the in vitro finding suggesting that FoxO3a may be involved in PGC-

Figure 3. Role of peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α) expression on amyloid precursor protein (APP) processing in neuronal cells. A, Fluorimetric assessment of α-, β-, and γ-secretase activities in Tg2576 neurons cultured with 91 or 273 mg/dL of glucose (to convert to millimoles per liter, multiply by 0.055) in response to adenoviral PGC-1α or control adenoviral green fluorescent protein (GFP) infection. Fifty-microgram cell lysates of each sample were used. B and C, Assessment of changes in soluble amyloid precursor protein α (sAPPα) concentration (B) and full-length APP (C) (expressed as percentage of total sAPP and actin immunoreactivity, respectively) in the same Tg2576 neurons cultured with 91 or 273 mg/dL of glucose in response to adenoviral PGC-1α or control adenoviral GFP infection. Results are expressed as a percentage of control (adenoviral GFP) infection. Values represent mean (SEM) of determinations made in 3 separate culture preparations; n=3 per culture preparation. *P < .05 vs control group by t test.
1α–mediated AD Aβ amyloidogenesis, we continued to explore the regulation of the FoxO3α mRNA and protein contents in the brain of AD cases relative to neurological control cases and the association of FoxO3α expression with PGC-1α and AD Aβ neuropathology.

We found that FoxO3α mRNA expression and FoxO3α protein contents in the hippocampal formation were significantly increased in the AD brain as a function of CDR, as assessed by quantitative real-time polymerase chain reaction (Figure 5A and eFigure B) (P=.001; R²=0.5416; 1-way ANOVA) and Western blot analysis (Figure 5B) (P=.004; R²=0.4528; 1-way ANOVA), respectively.

Moreover, we found a strong inverse association between PGC-1α and FoxO3α protein content in the same postmortem brain tissue (Pearson correlation coefficient, r²=-0.786; P<.001) (Figure 5C). Most importantly, we found that the increased in hippocampal FoxO3α protein content as a function of AD clinical dementia strongly associated with the increased density of neuritic plaques (Pearson correlation coefficient, r²=0.0001; P<.001) (Figure 5D). Finally, we found that the hippocampal FoxO3α protein content directly associated with total Aβ42 content in the EC-BM36/38 (Pearson correlation coefficient, r²=-0.411; P=.02) (Figure 5E), consistent with the hypothesis that decreased PGC-1α expression might causally promote AD Aβ amyloidogenesis through FoxO3α-mediated responses.

We report for the first time, to our knowledge, that PGC-1α expression is decreased in the brain of persons with AD as a function of dementia severity. Moreover, we found that experimental hyperglycemic conditions in cortico-hippocampal neuron cultures derived from Tg2576 embryos may significantly inhibit PGC-1α expression coincident with the elevation of Aβ peptide generation through a mechanism(s) involving the inactivation of nonamyloidogenic α-secretase processing of APP.36–38 Finally, the cause-effect relationship between PGC-1α and Aβ peptide generation was confirmed by the demonstration that exogenous viral expression of PGC-1α in primary Tg2576 cortico-hippocampal neurons reverse glucose-mediated induction of amyloidogenic Aβ peptide accumulation in the conditioned medium.

Previous studies from our laboratory found that that inhibition of FoxO3α activity by calorie restriction results in improved glucose use and promotes nonamyloidogenic-mediated α-secretase processing of APP precluding Aβ generation.39 Interestingly, in this study, we found that hyperglycemic conditions in vitro result in elevation of PGC-1α–dependent FoxO3α expression coincident with inhibition of nonamyloidogenic processing of APP and promotion of Aβ generation in Tg2576 neurons.

It was hypothesized that a close relationship exists among PGC-1α function, insulin sensitivity, and T2D, which is most likely related to the essential role of PGC-1α in mitochondria biogenesis and glucose/fatty acid metabolism. In this context, thiazolidinediones, an important class of antidiabetic drugs and agonists of PPAR-γ currently being developed for the treatment of AD, also act to increase insulin sensitivity coincident with the activation of PPAR-γ.40 The effects of thiazolidinediones are likely mediated through the ability of PGC-1α to acti-

**Figure 4.** Peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α) regulates amyloid precursor protein (APP) processing on β-amyloid (Aβ) generation involving modulation of forkheadlike transcription factor 1 (FoxO3α). A, Western blot analysis of FoxO3α protein content in Tg2576 neurons cultured with 91 or 273 mg/dL of glucose (to convert to millimoles per liter, multiply by 0.055) in response to adenoviral PGC-1α or control adenoviral green fluorescent protein (GFP) infection. B, Tg2576 neurons cultured with 91 mg/dL of glucose were infected with adenoviral PGC-1α or control adenoviral GFP in combination with adenoviral GFP or adenoviral constitutively active (CA) FoxO3α infection. The resulting culture-conditioned medium 24 hours postinfection was assessed for soluble amyloid precursor protein α (sAPPα) concentration (expressed as percentage of total sAPP immunoreactivity) by Western blot analysis.
vate mitochondria biogenesis and increase mitochondrial function and eventually improve energy metabolism. Moreover, recent evidence suggests that activation of SIRT1, an oxidized nicotinamide adenine dinucleotide–dependent deacetylase and a principal modulator of pathways downstream of calorie restriction that we found to prevent AD-type Aβ amyloidogenesis in Tg2576 mice,50 may also protect against experimental T2D conditions through inhibition of PGC-1α acetylation and promotion of PGC-1α activity.60

We hypothesize that impaired glucose/energy metabolism and increased steady-state concentration of cerebral glucose in the AD brain, as demonstrated by previous studies,24 lead to attenuation of PGC-1α expression resulting in activation of FoxO3a expression, thereby inhibiting nonamyloidogenic α-secretase processing of APP and increased generation of amyloidogenic Aβ peptides (Figure 6). The data suggest that cerebral glucose hypometabolism in AD may lead to an increased steady-state concentration of cerebral glucose as found in the

Figure 5. Peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α) expression inversely correlates with forkheadlike transcription factor 1 (FoxO3a) expression in the Alzheimer disease (AD) brain as a function of progression of clinical dementia. A, Forkheadlike transcription factor 1 messenger RNA (mRNA) content in hippocampal formation (quantified by real-time reverse transcriptase–polymerase chain reaction and normalized by neuron-specific enolase [NSE]) as a function of Clinical Dementia Rating (CDR). B, Western blot confirmation of increased FoxO3a protein contents in the hippocampal formation of AD cases. *P<.01, †P<.003, and ‡P<.05 vs control group by t test. C–E, Scatterplot analysis of FoxO3a protein expression (n=15) as a function of PGC-1α expression (C), Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 4-point scale (n=3, 4, 2, and 3 for CERAD scores of 0, 1, 3, and 5, respectively) for AD (D), or for content of β-amyloid (Aβ)42 (n=12) in the brain of AD cases (E). Straight line represents best linear regression fit.

Figure 6. Scheme illustrates the potential role of peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α) in regulation of nonamyloidogenic α-secretase processing of amyloid precursor protein (APP) through modulating forkheadlike transcription factor 1 (FoxO3a) in the Alzheimer disease (AD) brain. Aβ indicates β-amyloid.
AD brain,6 leading to alteration of PGC-1α–mediated multiple-cellular functions that ultimately result in AD amyloid neuropathology.

Accepted for Publication: November 25, 2008.

Correspondence: Giulio M. Pasinetti, MD, PhD, Department of Psychiatry and Neuroscience, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230, New York, NY 10029 (giulio.pasinetti@mssm.edu; for technical information, weiping.qin@mssm.edu).


Financial Disclosure: None reported.

Funding/SUPPORT: These studies were supported by the Dr Robert C. Atkins Foundation, National Institutes of Health grant AG14766, the Dana Foundation for Brain Research Initiative, Merit Review (Dr Pasinetti), and grant B4162C from the Department of Veterans Affairs Rehabilitation Research and Development Service.

Additional Information: The eTables and eFigure are available at http://archneur.amedeo.com.

REFERENCES


©2009 American Medical Association. All rights reserved.
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. 


Trial Registration Required. In concert with the International Committee of Medical Journal Editors (ICMJE), Archives of Neurology will require, as a condition of consideration for publication, registration of all trials in a public trials registry (such as http://ClinicalTrials.gov). Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2003. For trials that began enrollment before this date, registration will be required by September 13, 2005, before considering the trial for publication. The trial registration number should be supplied at the time of submission.

For details about this new policy, and for information on how the ICMJE defines a clinical trial, see the editorial by DeAngelis et al in the January issue of Archives of Dermatology (2005;141:76-77). Also see the Instructions to Authors on our Web site: www.archneurol.com.